Recent news releases
-
Feb 24, 2025 Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
-
Feb 5, 2025 Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride)
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch oxcarbazepine ER tablets in the United States
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
May 15, 2024 Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States